 DALLAS, March 23, 2021 PRNewswire -- Lantern Pharma Inc. NASDAQ: LTRN, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence A.I. platform to transform oncology drug discovery and development, will present new data on LP-184, a next-generation, targeted small molecule in the acylfulvene drug class, showcasing its potency across various 2D and 3D models of prostate cancer, at the American Association for Cancer Research AACR Virtual Annual Meeting, taking place from April 10-15, 2021. 